Home

Mark A Glickman

CIK 1441461 · Co-Chief Executive Officer · last filed 2026-08-28

Mark A Glickman is a Co-Chief Executive Officer who has filed 29 SEC Form 4 insider transactions across 8 companies since 2008. The most recent filing, for BSEM, was dated Aug 28, 2026. Across all open-market trades the lifetime net is −$1.5M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $3.7K across reported positions. 5 SEC filings were submitted jointly with CROFF ENTERPRISES INC.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$3.7K

Companies

8

Total Filings

29

Lifetime Open-Market Net

-$1.51M

Filer Profile

Reported Address
C/O METAVIA INC.
545 CONCORD AVENUE, SUITE 210
CAMBRIDGE, MA 02138
Related Filers
CROFF ENTERPRISES INC — 5 joint filings, latest 2022-12-09
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
BioStem Technologies, Inc. (BSEM) Delisted Director 7,671 — — $0 1 2026-08-28
MetaVia Inc. (NRBO) Delisted Director 20,629 $2.36 $48.7K $0 4 2026-06-08
TXMD Co-Chief Executive Officer 1,734 $2.16 $3.7K -$2.2K 4 2022-12-09
Esperion Therapeutics, Inc. (ESPR) Delisted Chief Commercial Officer 25,925 $3.18 $82.4K $0 1 2020-01-03
Aralez Pharmaceuticals Inc. (ARLZ) Delisted Chief Commercial Officer 250,188 — — $82.3K 7 2018-03-21
POZEN INC /NC (POZN) Delisted Chief Commercial Officer 29,137 — — $0 1 2015-06-24
AUXILIUM PHARMACEUTICALS INC (AUXL) Delisted EVP - Sales and Marketing 0 — — -$1.59M 10 2015-01-30
OSCIENT PHARMACEUTICALS CORP (OSCI) Delisted SVP, Sales & Marketing 36,157 — — $0 1 2008-07-30

Recent Filings

29 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2026-08-28 BioStem Technologies, Inc. (BSEM) Delisted Exer (M) +7,671 $0 EDGAR
2026-06-08 MetaVia Inc. (NRBO) Delisted Grant (A) +17,186 $0 EDGAR
2025-07-01 MetaVia Inc. (NRBO) Delisted Grant (A) +28,147 $0 EDGAR
2024-06-07 MetaVia Inc. (NRBO) Delisted Grant (A) +5,051 $0 EDGAR
2023-07-28 MetaVia Inc. (NRBO) Delisted Grant (A) +37,500 $0 EDGAR
2022-12-09 TXMD Mixed +1,294 -$2.2K EDGAR
2022-03-31 TXMD Grant (A) — $0 EDGAR
2022-03-28 TXMD Grant (A) — $0 EDGAR
2021-10-15 TXMD Grant (A) — $0 EDGAR
2020-01-03 Esperion Therapeutics, Inc. (ESPR) Delisted Grant (A) +5,925 $0 EDGAR
Showing 1–10 of 29
Page 1 of 3
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.